Innolake Biopharm was named as one of the Next Unicorn enterprises in Hangzhou

On April 28th, 2021, the fifth "Universe" Summit co-sponsored by Hangzhou Municipal People's Government, the CPC Zhejiang Province Committee of China National Democratic Construction Association and the Chinese Investor Association for Development and Promotion had a grand opening in the Hangzhou International Exposition Center. At the conference, the Hangzhou Venture Capital Association together with the one-stop entrepreneurial service platform “weLian”, released the “2021 Hangzhou Unicorn & Next Unicorn Enterprise list.” As of March 31st, 2021, there were 37 unicorn enterprises (valued at least 1 billion USD) and 209 next unicorn enterprises (valued at more than 100 million USD) in Hangzhou.

In the new next unicorn enterprise list, the number of healthcare enterprises has reached 47, ranking the first among all sectors. Notably, Innolake Biopharm was named as one of the Next Unicorn enterprises, for its innovative vision to create next generation therapeutics that will improve patients’ life around the world, in-house R&D capabilities and outstanding talents.

Unicorn and next unicorn enterprises are not only the foundation of industrial transformation, but also key elements of urban mass entrepreneurship and innovation. Under the guidance of the “14th Five-Year Plan”, Hangzhou City will uphold the belief of making Hangzhou “a digital, intelligent, and livable paradise” and strive for excellence in all aspects. The wave of innovation is constant, and the pioneers serve as a beacon for the followers. Hangzhou City will continue to support innovation with the utmost effort.